Inclusion Criteria

• For the HUMIRA treatment group
  • Children between the ages of 6 and 17 years inclusive at the time of enrollment
  • Diagnosed with moderately to severely active Crohn's Disease
  • Has been prescribed Humira therapy according to the local approved Humira product label
• For the immunosuppressant therapy treatment group
  • Children between the ages of 6 and 17 years inclusive at the time of enrollment
  • Diagnosed with moderately to severely active Crohn's Disease
  • Has been prescribed azathioprine, 6-mercaptopurine or methotrexate
• Parent or guardian or patient (if 18 years of age or older at enrollment and rolling over from an AbbVie-sponsored investigational Pediatric Crohn's Disease investigation trial) has voluntarily signed and dated an Authorization for Use/Disclosure of Data informed consent form after the nature of the registry has been explained and there has been the opportunity to ask questions

Exclusion Criteria

• Cannot be treated in accordance with the local Humira product label
• Is currently being treated with any investigational agents or is receiving any investigational procedures
• Should not be enrolled into the immunosuppressant therapy treatment group if they require ongoing treatment with approved biologic agents including HUMIRA